Global Opioid Induced Constipation Drugs Market by Drug Classes, Dosage Forms, Trends and Forecast to 2021

Opioids are a major class of analgesics and very effective for treating and managing pain. The class includes substances such as codeine, fentanyl, morphine, methadone, and oxycodone. However, constipation is a major gastrointestinal side effect caused due to long term opioid treatment in chronic pain patients. Constipation caused due to opioid is severe and is a major barrier to achieve satisfactory pain management in cancerous and noncancerous patients. Constipation, also called as opioid-induced -tramadol / hydrocodone / oxycodone / codeine – constipation, or opioid-induced constipation (OIC), which is a symptom in many patients taking these medications. To overcome this barrier, additional medicines are to be prescribed along with opioid to treat opioid induced constipation. Increasing number of chronic pain patients, growing acceptance of opioid to treat pain, and launch of new drugs to treat opioid induced constipation are major factors expected to drive the global opioid induced constipation drugs market during the forecast period.

Browse Opioid Induced Constipation Drugs Market by Dosage Form of Drugs (Solid, Semi-Solid, Liquid), and Drug Classes (Mu Opioid Receptor Antagonist, Chloride Channel Activator) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/opioid-induced-constipation-drugs-market/

The global opioid induced constipation drugs market segmentation is based on dosage form of the drug (solid, semi-solid, liquid), and drug classes (Mu opioid receptor antagonist, chloride channel activator). The global opioid induced constipation drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global opioid induced constipation drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global opioid induced constipation drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global opioid induced constipation drugs market and included in this report are AstraZeneca, Abbott Laboratories, Bayer, Boehringer Ingelheim, C.B. Fleet Company, Inc., Cosmo Pharmaceuticals, Daewoong Co. Ltd., Valeant, and Takeda Pharmaceutical Company Ltd.

1. Dosage Form
1.1 Solid Dosage Form
1.2 Semi-solid Dosage Form
1.3 Liquid Dosage Form

2. Drug Class
2.1 Mu Opioid Receptor Antagonist
2.2 Chloride Channel Activator
2.3 Others

3. Geography (Region, Country)
3.1 North America (U.S., Canada)
3.2 Latin America (Brazil, Mexico, Rest of LA)
3.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4 Asia Pacific (Japan, China, India, Rest of APAC)
3.5 Rest of the World

4. Company Profiles
4.1 Abbott Laboratories
4.2 AstraZeneca plc
4.3 Bayer AG
4.4 Boehringer Ingelheim GmbH
4.5 C.B. Fleet Company, Inc.
4.6 COSMO Pharmaceuticals
4.7 Daewoong Pharmaceuticals Co. Ltd.
4.8 Takeda Pharmaceutical Co., Ltd.
4.9 Valiant Pharmaceuticals International, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/opioid-induced-constipation-drugs-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.